Dutogliptin - Recardio

Drug Profile

Dutogliptin - Recardio

Alternative Names: Dutogliptin tartrate; PHX-1149; PHX1149T; REC-01

Latest Information Update: 19 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Phenomix Corporation
  • Developer Phenomix Corporation; RECARDIO
  • Class Antihyperglycaemics; Ischaemic heart disorder therapies; Pyrrolidines; Small molecules
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Type 2 diabetes mellitus

Highest Development Phases

  • Phase II Myocardial infarction
  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 25 Aug 2018 Pharmacokinetics, pharmacodynamics and adverse events data from a phase I trial in Myocardial infarction (MI) presented at the Annual Congress of the European Society of Cardiology (ESC-Card-2018)
  • 01 Aug 2018 Phase-II clinical trials in Myocardial infarction (Combination therapy) in USA, United Kingdom, Scotland, Poland, Netherlands, Hungary, Bulgaria, Belgium, Austria (SC) (NCT03486080)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top